Drugs / BAY1143269
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02439346 | Jun 2015 → Mar 2017 | — | Bayer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 1143269 | “BAY 1143269 is a potent and selective, orally administered novel inhibitor of mitogen-activated protein kinase interacting serine/threonine-protein kinase 1 (MKNK1).” NCT02439346 ↗ |
| Action | Inhibit | “inhibitor of mitogen-activated protein kinase interacting serine/threonine-protein kinase 1 (MKNK1)” NCT02439346 ↗ |
| Route | Oral | “orally administered” NCT02439346 ↗ |
| Target | MKNK1 | “inhibitor of mitogen-activated protein kinase interacting serine/threonine-protein kinase 1 (MKNK1)” NCT02439346 ↗ |